Gautam Jayram, MD: NIAGARA Trial Data Signal Survival Gains in Muscle Invasive Bladder Cancer: Urologist’s POV

Dr. Gautam Jayram highlights how adding durvalumab to standard gemcitabine–cisplatin chemotherapy in the NIAGARA trial improves event-free and overall survival without significantly increasing toxicity, reinforcing the value of a perioperative “sandwich” approach. He emphasizes the need to address ongoing undertreatment in community settings and advocates for a multidisciplinary strategy to optimize outcomes in patients with muscle-invasive bladder cancer.

MORE EXPERT PERSPECTIVES IN BLADDER CANCERS:

Petros Grivas, MD, PhD: Overview of NIAGARA Trial Data for Muscle Invasive Bladder Cancer

Petros Grivas, MD, PhD, of the University of Washington and Fred Hutch Cancer Center, reviewed the data from the Phase 3 NIAGARA trial, which demonstrated that adding durvalumab to neoadjuvant gemcitabine and cisplatin (GC) chemotherapy, followed by adjuvant durvalumab, significantly prolonged event-free and overall survival in cisplatin-eligible patients with localized muscle invasive bladder cancer.